AC Immune SA (ACIU) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AC Immune SA has entered into a significant Option and License Agreement with Takeda Pharmaceuticals, USA, Inc., granting Takeda an exclusive option to license AC Immune’s intellectual property for the development, manufacture, and commercialization of specific compounds and products. The agreement, effective as of May 11, 2024, details the terms and conditions under which Takeda can exercise this option, symbolizing a strategic collaboration between the two companies in the pharmaceutical industry.
For further insights into ACIU stock, check out TipRanks’ Stock Analysis page.